RVNC Revance Therapeutics Inc.

15.17
-0.16  -1%
Previous Close 15.33
Open 15.21
Price To Book 3.54
Market Cap 669,035,410
Shares 44,102,532
Volume 587,825
Short Ratio
Av. Daily Volume 388,729
Stock charts supplied by TradingView

NewsSee all news

  1. Revance Appoints Mark J. Foley as President and CEO, Replacing Dan Browne

    - Mark Foley to lead company as it gears up to commercialize next-generation neuromodulator – - Change in leadership unrelated to company performance - - Revance on track to submit BLA for DAXI for the treatment of

  2. Revance Earns Great Place to Work® Certification for Second Year

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced the company is certified as a great workplace by

  3. Revance to Participate in the 2019 Cantor Global Healthcare Conference

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the 2019

  4. Revance to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Morgan

  5. Revance to Participate in the Wells Fargo 14th Annual Healthcare Conference

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Wells

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 completion of enrolment due 4Q 2019.
DAXI (RT002)
Plantar fasciitis
Phase 2 top-line data due 1H 2020.
DAXI (RT002)
Lateral Canthal (Crow’s Feet) Lines
Phase 3 completion of enrolment due 4Q 2019.
DAXI (RT002) - ASPEN
Cervical dystonia
BLA filing due fall of 2019.
DAXI (RT002)
Moderate to severe glabellar (frown) lines
Phase 2 trial to be initiated in 2020.
DAXI (RT002)
Chronic migraine
Phase 2 completion of enrolment due 1H 2020.
DAXI (RT002)
Upper limb spasticity
Phase 2 top-line data due 1H 2020.
DAXI (RT002)
Forehead lines

Latest News

  1. Revance Appoints Mark J. Foley as President and CEO, Replacing Dan Browne

    - Mark Foley to lead company as it gears up to commercialize next-generation neuromodulator – - Change in leadership unrelated to company performance - - Revance on track to submit BLA for DAXI for the treatment of

  2. Revance Earns Great Place to Work® Certification for Second Year

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced the company is certified as a great workplace by

  3. Revance to Participate in the 2019 Cantor Global Healthcare Conference

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the 2019

  4. Revance to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Morgan

  5. Revance to Participate in the Wells Fargo 14th Annual Healthcare Conference

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Wells